Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
FPI-2265 by Fusion Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
FPI-2265 is under clinical development by Fusion Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Data Insights
FPI-2265 by Fusion Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
FPI-2265 is under clinical development by Fusion Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...